Johnson & Johnson Share Holder Equity 2010-2024 | JNJ
Johnson & Johnson share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
- Johnson & Johnson share holder equity for the quarter ending March 31, 2024 was $68.774B, a 10.46% decline year-over-year.
- Johnson & Johnson share holder equity for 2023 was $68.774B, a 10.46% decline from 2022.
- Johnson & Johnson share holder equity for 2022 was $76.804B, a 3.76% increase from 2021.
- Johnson & Johnson share holder equity for 2021 was $74.023B, a 16.98% increase from 2020.
Johnson & Johnson Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$68,774 |
| 2022 |
$76,804 |
| 2021 |
$74,023 |
| 2020 |
$63,278 |
| 2019 |
$59,471 |
| 2018 |
$59,752 |
| 2017 |
$60,160 |
| 2016 |
$70,418 |
| 2015 |
$71,150 |
| 2014 |
$69,752 |
| 2013 |
$74,053 |
| 2012 |
$64,826 |
| 2011 |
$57,080 |
| 2010 |
$56,579 |
| 2009 |
$50,588 |
Johnson & Johnson Quarterly Share Holder Equity
(Millions of US $) |
| 2023-12-31 |
$68,774 |
| 2023-09-30 |
$71,228 |
| 2023-06-30 |
$76,409 |
| 2023-03-31 |
$70,869 |
| 2022-12-31 |
$76,804 |
| 2022-09-30 |
$74,599 |
| 2022-06-30 |
$76,357 |
| 2022-03-31 |
$74,709 |
| 2021-12-31 |
$74,023 |
| 2021-09-30 |
$70,272 |
| 2021-06-30 |
$69,580 |
| 2021-03-31 |
$65,834 |
| 2020-12-31 |
$63,278 |
| 2020-09-30 |
$64,473 |
| 2020-06-30 |
$62,978 |
| 2020-03-31 |
$61,294 |
| 2019-12-31 |
$59,471 |
| 2019-09-30 |
$58,210 |
| 2019-06-30 |
$60,785 |
| 2019-03-31 |
$58,955 |
| 2018-12-31 |
$59,752 |
| 2018-09-30 |
$64,626 |
| 2018-06-30 |
$62,889 |
| 2018-03-31 |
$63,255 |
| 2017-12-31 |
$60,160 |
| 2017-09-30 |
$73,979 |
| 2017-06-30 |
$71,922 |
| 2017-03-31 |
$70,341 |
| 2016-12-31 |
$70,418 |
| 2016-09-30 |
$72,769 |
| 2016-06-30 |
$72,473 |
| 2016-03-31 |
$72,647 |
| 2015-12-31 |
$71,150 |
| 2015-09-30 |
$71,554 |
| 2015-06-30 |
$71,131 |
| 2015-03-31 |
$67,878 |
| 2014-12-31 |
$69,752 |
| 2014-09-30 |
$76,591 |
| 2014-06-30 |
$78,048 |
| 2014-03-31 |
$76,582 |
| 2013-12-31 |
$74,053 |
| 2013-09-30 |
$69,804 |
| 2013-06-30 |
$69,665 |
| 2013-03-31 |
$66,855 |
| 2012-12-31 |
$64,826 |
| 2012-09-30 |
$63,761 |
| 2012-06-30 |
$60,434 |
| 2012-03-31 |
$61,366 |
| 2011-12-31 |
$57,080 |
| 2011-09-30 |
$61,527 |
| 2011-06-30 |
$62,132 |
| 2011-03-31 |
$59,863 |
| 2010-12-31 |
$56,579 |
| 2010-09-30 |
$57,291 |
| 2010-06-30 |
$52,851 |
| 2010-03-31 |
$52,914 |
| 2009-12-31 |
$50,588 |
| 2009-09-30 |
$50,384 |
| 2009-06-30 |
$46,247 |
| 2009-03-31 |
$43,791 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$360.407B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
